Literature DB >> 29224643

Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.

Paul L Hess1, Kevin Kennedy2, Michael Cowherd3, Salim S Virani4, Frederick A Masoudi3, Ann Marie Navar5, Robert W Yeh6, P Michael Ho7, Thomas M Maddox8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29224643      PMCID： PMC5961484          DOI： 10.1016/j.ahj.2017.09.004

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  4 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

2.  Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs.

Authors:  Salim S Virani; Julia M Akeroyd; Vijay Nambi; Paul A Heidenreich; Pamela B Morris; Khurram Nasir; Erin D Michos; Vera A Bittner; Laura A Petersen; Christie M Ballantyne
Journal:  Circulation       Date:  2017-05-02       Impact factor: 29.690

3.  Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

Authors:  Dhruv S Kazi; Joanne Penko; Pamela G Coxson; Andrew E Moran; Daniel A Ollendorf; Jeffrey A Tice; Kirsten Bibbins-Domingo
Journal:  JAMA       Date:  2017-08-22       Impact factor: 56.272

4.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245
  4 in total
  2 in total

1.  Liver-selective γ-secretase inhibition ameliorates diet-induced hepatic steatosis, dyslipidemia and atherosclerosis.

Authors:  KyeongJin Kim; Junjie Yu; Jin Ku Kang; John P Morrow; Utpal B Pajvani
Journal:  Biochem Biophys Res Commun       Date:  2020-05-18       Impact factor: 3.575

2.  Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States.

Authors:  Alexa C Klimchak; Miraj Y Patel; Şerban R Iorga; Natasha Kulkarni; Nathan D Wong
Journal:  Am J Prev Cardiol       Date:  2020-05-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.